These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22167109)

  • 21. The meaning of community consultation.
    Schmidt TA; Delorio NM; McClure KB
    Am J Bioeth; 2006; 6(3):30-2; discussion W46-8. PubMed ID: 16754446
    [No Abstract]   [Full Text] [Related]  

  • 22. Commentary: an imperfect compromise.
    Dennis M
    BMJ; 2003 Aug; 327(7409):286. PubMed ID: 12896946
    [No Abstract]   [Full Text] [Related]  

  • 23. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee.
    Naqvi HA
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298
    [No Abstract]   [Full Text] [Related]  

  • 24. Data monitoring committees and randomized clinical trials.
    Trachtman H; Caplan AL
    Kidney Int; 2019 Apr; 95(4):992. PubMed ID: 30904070
    [No Abstract]   [Full Text] [Related]  

  • 25. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.
    Tharmanathan P; Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044
    [No Abstract]   [Full Text] [Related]  

  • 26. Commentary on Fleming et al.: Data monitoring committee evidence base needed.
    Terrin M
    Clin Trials; 2017 Apr; 14(2):124-125. PubMed ID: 28142249
    [No Abstract]   [Full Text] [Related]  

  • 27. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data Monitoring Committees.
    Novack GD
    Ocul Surf; 2010 Jan; 8(1):40-3. PubMed ID: 20105406
    [No Abstract]   [Full Text] [Related]  

  • 29. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
    [No Abstract]   [Full Text] [Related]  

  • 30. Reporting of ethical requirements in phase III surgical trials.
    Bridoux V; Schwarz L; Moutel G; Michot F; Herve C; Tuech JJ
    J Med Ethics; 2014 Oct; 40(10):687-90. PubMed ID: 23959837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disclosure of financial competing interests in randomised controlled trials: cross sectional review.
    Gross CP; Gupta AR; Krumholz HM
    BMJ; 2003 Mar; 326(7388):526-7. PubMed ID: 12623910
    [No Abstract]   [Full Text] [Related]  

  • 32. Continuous safety monitoring for randomized controlled clinical trials.
    Piller LB; Silverman MH; Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S1. PubMed ID: 21458597
    [No Abstract]   [Full Text] [Related]  

  • 33. Is it ethical to keep interim findings of randomised controlled trials confidential?
    Miller FG; Wendler D
    J Med Ethics; 2008 Mar; 34(3):198-201. PubMed ID: 18316463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interim monitoring of efficacy data is important and appropriate.
    Sydes MR; Parmar MK
    J Clin Epidemiol; 2008 Mar; 61(3):203-4. PubMed ID: 18226741
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic beneficence and patient recruitment in randomized controlled clinical trials.
    Mann H
    Am J Bioeth; 2002; 2(2):35-6. PubMed ID: 12189074
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters.
    Shah SK; Eckstein L; Ibrahim A
    Clin Trials; 2023 Aug; 20(4):452-454. PubMed ID: 37231704
    [No Abstract]   [Full Text] [Related]  

  • 37. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trials in oncology stopped early for benefit.
    Wilcox RA; Djulbegovic B; Moffitt HL; Guyatt GH; Montori VM
    J Clin Oncol; 2008 Jan; 26(1):18-9. PubMed ID: 18165635
    [No Abstract]   [Full Text] [Related]  

  • 39. Interim analysis in randomized trials: DAMOCLES' sword?
    Besselink MG; van der Graaf Y; Gooszen HG
    J Clin Epidemiol; 2010 Apr; 63(4):353-4. PubMed ID: 19959333
    [No Abstract]   [Full Text] [Related]  

  • 40. Secrecy for data monitoring committees: inferior ethics, bad policy.
    Wells RJ
    J Clin Oncol; 1998 Jan; 16(1):390-1. PubMed ID: 9440771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.